

## **Accepted Article**

Title: Selective Asymmetric Transfer Hydrogenation of α-Substituted Acetophenones with Bifunctional Oxo-Tethered Ruthenium(II) Catalysts

Authors: Yamato Yuki, Taichiro Touge, Hideki Nara, Kazuhiko Matsumura, Mitsuhiko Fujiwhara, Yoshihito Kayaki, and Takao Ikariya

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: Adv. Synth. Catal. 10.1002/adsc.201701227

Link to VoR: http://dx.doi.org/10.1002/adsc.201701227

UPDATE

# Selective Asymmetric Transfer Hydrogenation of α-Substituted Acetophenones with Bifunctional Oxo-Tethered Ruthenium(II) Catalysts

Yamato Yuki,<sup>a,\*</sup> Taichiro Touge,<sup>a</sup> Hideki Nara,<sup>a</sup> Kazuhiko Matsumura,<sup>a</sup> Mitsuhiko Fujiwhara,<sup>a</sup> Yoshihito Kayaki,<sup>b,\*</sup> and Takao Ikariya<sup>b,c</sup>

<sup>a</sup> Corporate Research & Development Division, Takasago International Corporation, 1-4-11 Nishi-Yawata, Hiratsuka, Kanagawa, 254-0043, Japan

<sup>b</sup> Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Tokyo Institute of Technology, 2-12-1-E4-1 O-okayama, Meguro-ku, Tokyo 152-8552, Japan Email: yamato\_yuki@takasago.com, ykayaki@o.cc.titech.ac.jp

<sup>c</sup> Deceased on April 21, 2017.

Received: ((will be filled in by the editorial staff))

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/adsc.201#######.((Please delete if not appropriate))

Abstract. A practical method for the asymmetric transfer hydrogenation of a-substituted ketones was developed utilizing oxo-tethered N-sulfonyldiamine-ruthenium complexes. Reduction by HCO<sub>2</sub>H and HCO<sub>2</sub>K in a mixed solvent of EtOAc/H2O allowed for the selective synthesis of halohydrins from 2-bromoacetophenone (98%) and 2chloroacetophenone (>99%), leading to suppressed undesired side reactions stemming from formylation under the typical reaction conditions using an azeotropic 5:2 mixture of HCO<sub>2</sub>H and Et<sub>3</sub>N. A range of functional groups, such as halogens, methoxy, nitro, dimethylamino, and ester groups, were well tolerated, highlighting the potential of this method. Nearly complete selectivity with a preferable ee was maintained even with a substrate/catalyst (S/C) ratio of 5000. This catalyst system was also effective for the asymmetric reduction of a-sulfonated ketones without eroding the leaving group.

**Keywords:** asymmetric catalysis; asymmetric transfer hydrogenation; ruthenium; α-haloketones; halohydrins

Asymmetric transfer hydrogenation (ATH) of prochiral ketones is one of the most extensively researched areas in the synthesis of chiral secondary alcohols.<sup>[1]</sup> Compared with asymmetric hydrogenation, ATH without hazardous hydrogen gas ensures several advantages, such as mild reaction conditions and a simple and safe operation. Based on the crucial role of protic amine ligands in the asymmetric reduction of polar carbon-oxygen and carbon-nitrogen double bonds, Noyori's well-defined chiral Ru(II) catalysts, such as RuCl(TsDPEN)(pcymene) (1; TsDPEN = N-(p-toluenesulfonyl)-1,2diphenylethylenediamine), have proven to be applicable to ATH of various prochiral ketones. ATH has become a viable option in the industrial

production of chemical compounds, particularly active pharmaceutical ingredients (APIs).<sup>[2]</sup> In the context of our ongoing interest in accessing synthetically valuable chiral alcohols, the ATH of  $\alpha$ bromoacetophenone is a remaining challenge. Optically pure 2-bromo-1-arylethanols and the related 2-amino-1-arylethanols are key intermediates of pharmaceuticals, such as  $\beta$ -adrenergic receptor agonists;<sup>[2d,3]</sup> however, it has been reported that  $\alpha$ bromoketones decompose under ATH conditions using a mixture of HCO<sub>2</sub>H/Et<sub>3</sub>N.<sup>[2d,4a]</sup> The Coreyreduction<sup>[3c,3e-f,5]</sup> and a Bakshi-Shibata (CBS) biocatalytic reaction<sup>[6]</sup> have been alternatively executed for this purpose. In reasonable efforts to utilize formic acid and its analogues as convenient reducing agents for the enantioselective reduction of  $\alpha$ -bromoketone,<sup>[3e,4]</sup> specially modified water-soluble ligands or surfactants were treated in an aqueousphase ATH reaction to dissolve hydrophobic metal complexes in the reaction media. Although some rhodium and iridium catalysts have provided more satisfactory results than the ruthenium system, a comparatively substantial amount of expensive catalyst was used (typically with a substrate/catalyst ratio (S/C) of 100).<sup>[4d,e,j]</sup> A one-pot sequential process involving a Au-catalyzed hydration of arylsubstituted bromoalkynes and the ATH of the resulting bromomethyl ketones, which was recently examined as a practical approach for the construction of chiral aromatic bromohydrins, was conducted IPrAuNTf<sub>2</sub> using 1.5 mol% each of and RuCl(TsDPEN)(η<sup>6</sup>-mesitylene).<sup>[4i]</sup>

In our previous studies, advanced oxo-tethered ruthenium complexes (S,S)-2 and (S,S)-3<sup>[7,8]</sup> showed much higher activity in the ATH of acetophenone (with up to S/C = 30,000) than the prototypical ATH catalyst 1 (Figure 1).<sup>[1a-e,7a]</sup> Herein, we report a new application of the oxo-tethered complexes for the

reduction of  $\alpha$ -bromoketone and related substituted acetophenones having good leaving groups, leading to exceptionally high product selectivity.

Figure 1. Structure of non-tethered and tethered Ru-DPEN catalysts.





SO<sub>2</sub>R= Ts (S,S)-**2** TsDENEB Ms (S,S)-**3** MsDENEB

Our initial study started with the ATH of 2bromoacetophenone (4a) as a model substrate at 60 °C for 4 h. The results are summarized in Table 1. When (R,R)-1 was used as a catalyst in a 5:2 mixture of HCO<sub>2</sub>H and Et<sub>3</sub>N (run 1), 4a was mostly consumed as expected, and only a trace amount of bromohydrin (5a) was detected by GC analysis. Upon changing the catalyst to the oxo-tethered complex (S,S)-2, the yield of 5a slightly increased to 4% (run 2). Although no marked effect was observed using EtOAc as a solvent (run 3), the addition of water was found to give (R)-5a with 40% selectivity and 96% ee (run 4). Gratifyingly, a combined use of HCO<sub>2</sub>H and HCO<sub>2</sub>K, instead of a HCO<sub>2</sub>H/Et<sub>3</sub>N azeotrope, drastically enhanced the selectivity up to 98% (run 5). Among the tested solvents (runs 5-10), BuOAc and toluene also showed acceptable selectivities, albeit with somewhat lower catalytic activities (runs 6 and 7). The use of methanol and THF gave rise to rather poor product selectivities (runs 8 and 9). Although a more favorable result with an excellent yield and 97% ee was obtained for CHCl<sub>3</sub> (run 10), we preferred to use EtOAc as a desirable solvent from both an environmental and practical point of view. When the reaction was conducted without HCO<sub>2</sub>K, the catalytic activity, selectivity, and optical purity dropped noticeably (run 11). It should be noted that the conversion and selectivity to (R)-5a dramatically reverted in the presence of only 0.1 equiv. of HCO<sub>2</sub>K (run 12), and the further addition of an excess amount of HCO<sub>2</sub>K led to an increase in the enantioselectivity and a slight decrease in the chemoselectivity (run 13). A considerable decrease in the product selectivity using HCO<sub>2</sub>K as the sole hydrogen source signified that HCO<sub>2</sub>H and HCO<sub>2</sub>K were both indispensable for the exquisite catalytic performance (run 14). Eventually, it turned out that the combined use of 3.0 equiv. of HCO<sub>2</sub>H and 1.0 equiv. of HCO<sub>2</sub>K was optimal for this reaction.

Further study on the ATH of 4a with (*S*,*S*)-2 in a HCO<sub>2</sub>H/Et<sub>3</sub>N azeotrope (run 2 of Table 1) by GC and LC-MS analyses revealed that cyclic carbonate (A)

and a formate derivative (**B**) were produced in 53% and 35% yields, respectively, accompanied with small amounts of  $\alpha$ -hydroxyketone (**C**) and glycol diformate (**D**) as shown in Scheme 1. Debrominated acetophenone or 1-phenylethanol was not confirmed in the product mixture. The formation of **A** and **B** is in accordance with previously reported results<sup>[2d,4a]</sup>.

**Scheme 1.** Formation of byproducts in the typical ATH system using HCO<sub>2</sub>H/Et<sub>3</sub>N.



According to the relevant carbonate formation mechanism in the ATH of  $\alpha$ -sulfonated acetophenone by the Wills' group, the formation of A by debromination of 4a is conceivable, as shown in-Scheme 2.<sup>[9]</sup> With the progress of the ATH of 4a, the alcoholic group of 5a can trap  $CO_2$  in the presence of Et<sub>3</sub>N, followed by concomitant cyclization and debromination to afford A. Considering the formate anion in the azeotrope, debromination leading to **B** is ascribed to the nucleophilic substitution of 4a or 5a by  $HCO_2^{-}$ . Based on these mechanistic aspects, high selectivity of the present HCO2H/HCO2K ATH system was realized by eliminating Et<sub>3</sub>N, which is intimately involved in the formation of the debromination products A and B. Actually, formate B was obtained as a sole product in 32% yield, when bromohydrin 5a was treated under the ATH conditions using HCO<sub>2</sub>H/Et<sub>3</sub>N. Carbonate A was not formed in this experiment because of the absence of  $CO_2$ . When **5a** was subject to the ATH conditions under CO<sub>2</sub> atmosphere, formation of carbonate A from bromohydrin was verified by GC/MS analysis. In contrast, the Et<sub>3</sub>N-free HCO<sub>2</sub>H/HCO<sub>2</sub>K system in a mixture of EtOAc and H2O could suppress such excessive side reactions via 5a.

#### Table 1. ATH of 4a using bifunctional DPEN-derived Ru catalysts.<sup>[a]</sup>

4a



Run	Catalyst	Reducing agent (equiv.)	Solvent	Conv. [%] <sup>[b]</sup>	Select. for <b>5a</b> [%] <sup>[b]</sup>	Ee [%] <sup>[b]</sup>	
1 <sup>[c]</sup>	( <i>R</i> , <i>R</i> )- <b>1</b>	HCO <sub>2</sub> H/Et <sub>3</sub> N	-	100	trace	n.d.	
2 <sup>[c]</sup>	(S,S)-2	HCO <sub>2</sub> H/Et <sub>3</sub> N	-	100	4	87	
3 <sup>[c][d]</sup>	(S,S)-2	HCO <sub>2</sub> H/Et <sub>3</sub> N	EtOAc	100	6	97	
4 <sup>[c][d][e]</sup>	(S,S)-2	HCO <sub>2</sub> H/Et <sub>3</sub> N	EtOAc/H <sub>2</sub> O	100	40	96	
5 <sup>[d][e]</sup>	(S,S)-2	$HCO_2H(3)/HCO_2K(1)$	EtOAc/H <sub>2</sub> O	100	98	95	
6 <sup>[d][e]</sup>	(S,S)-2	$HCO_2H(3)/HCO_2K(1)$	BuOAc/H <sub>2</sub> O	86	>99	95	
7 <sup>[d][e]</sup>	(S,S)-2	$HCO_2H(3)/HCO_2K(1)$	toluene/H <sub>2</sub> O	88	97	96	
8 <sup>[d][e]</sup>	(S,S)-2	$HCO_2H(3)/HCO_2K(1)$	MeOH/H <sub>2</sub> O	100	71	94	÷.
9 <sup>[d][e]</sup>	(S,S)-2	$HCO_2H(3)/HCO_2K(1)$	THF/H <sub>2</sub> O	93	90	94	
10 <sup>[d][e]</sup>	(S,S)-2	$HCO_2H(3)/HCO_2K(1)$	CHCl <sub>3</sub> /H <sub>2</sub> O	100	>99	97	
11 <sup>[d][e]</sup>	(S,S)-2	$HCO_2H(3)$	EtOAc/H <sub>2</sub> O	69	94	93	
12 <sup>[d][e]</sup>	(S,S)-2	HCO <sub>2</sub> H(3)/HCO <sub>2</sub> K(0.1)	EtOAc/H <sub>2</sub> O	100	98	93	
13 <sup>[d][e]</sup>	(S,S)-2	$HCO_2H(3)/HCO_2K(4)$	EtOAc/H <sub>2</sub> O	100	96	96	
14 <sup>[d][e]</sup>	( <i>S</i> , <i>S</i> )- <b>2</b>	$HCO_2K(2)$	EtOAc/H <sub>2</sub> O	83	63	96	

<sup>[a]</sup> Typical reaction conditions; substrate (5 mmol), ruthenium catalyst (S/C = 100 for (*R*,*R*)-1 or S/C = 1000 for (*S*,*S*)-2). <sup>[b]</sup> Determined by GC analysis using a CHIRALSIL-DEX-CB column.

<sup>[c]</sup> The amount of HCO<sub>2</sub>H/Et<sub>3</sub>N (5:2 azeotropic mixture) used was 2.5 mL.

<sup>[d]</sup> The amount of organic solvent used was 2.5 mL.

<sup>[e]</sup> The amount of H<sub>2</sub>O used was 4 mL.

Scheme 2. Plausible mechanism of the formation of byproduct A.



This ATH system was also found to be applicable to 2-chloroacetophenone 6a under similar conditions as the reaction of 4a with S/C of 1000.<sup>[8c,10]</sup> As summarized in Table 2, the oxo-tethered catalyst bearing a Ms group, (S,S)-3, exhibited prominent catalytic performance identical to the Ts-substituted analog, (S,S)-2. Both substrates having an electrondonating group (run 3) and an electron withdrawing group (runs 2, 5 and 7) on the aromatic ring were converted to the corresponding (R)-alcohols in preferable enantioselectivities, whereas the orthofluorinated substrate 6f provided a lower optical purity (run 6). Despite the electron-donating nature of the dimethylamino substituent on the aromatic ring, the ATH of **6h** required an extended reaction time of

and resulted in a somewhat 8 h lower enantioselectivity (87% ee, run 8). When the catalys. amount was reduced to S/C = 5000, **6a** was successfully converted to the corresponding (R)alcohol with same selectivity and ee in a prolonged reaction time of 13.5 h (run 9).

Table 3 summarizes the substrate scope of  $\alpha$ bromoacetophenones for the HCO<sub>2</sub>H/HCO<sub>2</sub>K ATH system. In some cases (runs 4 and 5 in Table 3), slightly lower isolated yields were obtained for the reaction of 4d and 4e, compared with the results of the  $\alpha$ -chloroacetophenone derivatives **6d** and **6e** in runs 4 and 5 of Table 2. The substrate with an electron withdrawing group on the aromatic ring resulted in a reduced optical purity (run 6), whereas electron-donating groups led to satisfactory results (runs 1-2, 4). Halogen atoms attached to the aromatic ring remained intact under the ATH conditions (runs 3, 7, and 9). These tendencies are similar to the outcomes of the  $\alpha$ -chlorinated acetophenones in Table 2. It is striking that the unprecedented iodinesubstituted substrates (4i and 6g) and the corresponding products (5i and 7g) did not deteriorate the catalyst performance.<sup>[11]</sup> A substrate with an ester group 4i could also be chemoselectively transformed into the desired alcohol in a favorable isolated yield and enantioselectivity (run 10). In addition, the oxotethered Ru complexes were able to reduce aliphatic ketones *tert*-butyl halomethyl good in enantioselectivities of 50-70% (Table S1).<sup>[12]</sup>

Table 2. ATH of 2-chloroacetophenone derivatives catalyzed by oxo-tethered Ru complexes.<sup>[a]</sup>



Run	Catalyst	$\mathbb{R}^1$	$\mathbb{R}^2$	Product	Isolated yield [%]	Ee [%]
1	( <i>S</i> , <i>S</i> )- <b>3</b>	-H	-H	7a	92	95 <sup>[b]</sup> ( <i>R</i> )
2	( <i>S</i> , <i>S</i> )- <b>3</b>	-Cl	-H	7b	94	93 <sup>[b]</sup> ( <i>R</i> )
3	(S,S)-2	-OMe	-H	7c	98	94 <sup>[b]</sup> ( <i>R</i> )
4	(S,S)-2	-Ph	-H	7d	94	95 <sup>[b]</sup> ( <i>R</i> )
5	( <i>S</i> , <i>S</i> )- <b>3</b>	-F	-H	7e	94	92 <sup>[b]</sup> ( <i>R</i> )
6	(S,S)- <b>3</b>	-F	-F	7f	92	79 <sup>[b]</sup> ( <i>R</i> )
7	(S,S)- <b>3</b>	-I	-H	7g	96	$94^{[c]}(R)$
8 <sup>[d]</sup>	(S,S)-2	-NMe <sub>2</sub>	-H	7h	90	87 <sup>[c]</sup> (-)
9 <sup>[e]</sup>	(S,S)- <b>3</b>	-H	-H	7a	95	$96^{[b]}(R)$

<sup>[a]</sup> Typical reaction conditions: substrate (5 mmol), EtOAc (2.5 mL), H<sub>2</sub>O (4 mL).

<sup>[b]</sup> Determined by GC analysis using a CHIRALSIL-DEX-CB column.

<sup>[c]</sup> Determined by HPLC analysis.

<sup>[d]</sup> Reaction time = 8 h.

<sup>[e]</sup> Substrate (50 mmol), EtOAc (25 mL),  $H_2O$  (40 mL), S/C = 5000, 13.5 h.

Table 3. ATH of 2-bromoacetophenone derivatives catalyzed by oxo-tethered Ru complexes.<sup>[a]</sup>

	R <sup>2</sup>	Br HCO	2H (3 equiv.)	catalyst (S/C = 1	000) R <sup>2</sup>	OH R <sup>2</sup> Br	
	R <sup>1</sup>		₂K (1 equiv.)	EtOAc/H <sub>2</sub> O 60 °C, 4 h			
	4a - 4i				5a - 5i		
					conv. 100	%	
Run	Catalyst	$\mathbb{R}^1$	<b>R</b> <sup>2</sup>	Product	Isolated yield [%]	Ee [%]	
1	(S,S)-2	-H	-H	5a	93	96 <sup>[b]</sup> ( <i>R</i> )	
2	(S,S)-2	-OMe	-H	5b	88	96 <sup>[b]</sup> ( <i>R</i> )	
3	(S,S)-2	-Br	-H	5c	90	94 <sup>[b]</sup> (R)	
4	( <i>S</i> , <i>S</i> )- <b>3</b>	-Ph	-H	5d	86	97 <sup>[b]</sup> (R)	
5	( <i>S</i> , <i>S</i> )- <b>3</b>	-F	-H	5e	86	93 <sup>[b]</sup> (R)	
6	( <i>S</i> , <i>S</i> )- <b>3</b>	-H	$-NO_2$	5f	86	$82^{[b]}(R)$	
7	(S,S)-2	-Cl	-H	5g	92	93 <sup>[b]</sup> (R)	
8	(S,S)-2	-CF <sub>3</sub>	-H	5 <b>h</b>	94	$94^{[b]}(R)$	
9	( <i>S</i> , <i>S</i> )- <b>3</b>	-I	-H	5i	96	$91^{[c]}(R)$	
10 <sup>[d]</sup>	( <i>S</i> , <i>S</i> )- <b>2</b>	-OAc	-H	5j	93	95 <sup>[c]</sup> (-)	

<sup>[a]</sup> Typical reaction conditions: substrate (5 mmol), EtOAc (2.5 mL), H<sub>2</sub>O (4 mL).

<sup>[b]</sup> Determined by GC analysis using a CHIRALSIL-DEX-CB column.

<sup>[c]</sup> Determined by HPLC analysis.

<sup>[d]</sup> An elongated reaction time of 6 h.

The ATH of  $\alpha$ -sulfonated acetophenones<sup>[10b,13]</sup> is also of interest because sulfonates substituents, such as mesylate and tosylate, are good leaving groups accessible to further transformations.<sup>[14]</sup> Nevertheless, the previous study has been confined to the use of expensive Rh catalysts bearing a bifunctional Nsulfonyl DPEN ligand. From the results shown in Scheme 3, these substrates could be hydrogenated successfully in similar high isolated yields and enantioselectivities even with a S/C ratio of 1000 as above demonstrated for the  $\alpha$ -chloroacetophenone family.

**Scheme 3.** ATH of  $\alpha$ -sulfonated acetophenone derivatives.



Regarding the derivatization of the obtained optically active haloalcohols, (*R*)-2-chloro-1-phenylethan-1-ol **7d** was completely converted into the corresponding chiral (*R*)-epoxide **10** which is convertible to various important chiral compounds such as 2-amino-1-alcohol<sup>[15a,b]</sup>,  $\beta$ -azido alcohol<sup>[15b]</sup>, and  $\beta$ -methoxy alcohol<sup>[15d]</sup> (Scheme 4).

Scheme 4. Derivatization of chiral  $\alpha$ -chlorohydrin.



The catalytic ATH system also proved effective for the stereoselective synthetic route to BMS-960, a potent S1P<sub>1</sub> receptor agonist, as an alternative to the reported borane and enzymatic reaction<sup>[15c,e]</sup>. With slightly modified reaction conditions, the highlighted asymmetric reduction of bromomethyl 4-cyanophenyl ketone **11** with (*S*,*S*)-**3** afforded (*R*)-(-)-4-(2-bromo-1-hydroxyethyl)benzonitrile **12** in 87% isolated yield and 88% ee (Scheme 5). Unlike the biocatalytic and CBS reduction, the ATH system using the (*R*,*R*)catalyst appropriate for the desired alcohol offers a highly reliable catalytic method free from the concerns of substrate specificity and generating equivalent amounts of boron waste.

Scheme 5. Synthesis of an intermediate to BMS960 by ATH.



In summary, we developed the effective ATH reaction system for  $\alpha$ -substituted acetophenones, as typified by  $\alpha$ -bromoketone derivatives. The oxotethered Ru complexes (S,S)-2 and (S,S)-3 served well catalyst combination as a in with HCO<sub>2</sub>H/HCO<sub>2</sub>K in aqueous EtOAc to provide a range of chiral secondary alcohols with useful functional groups accessible further to transformations. This ATH system is a more practical way to ensure extremely high selectivity than previously reported methods, associated with a significant reduction of the byproduct formation.

### **Experimental Section**

Procedure for the asymmetric transfer hydrogenation of 2-bromoacetophenone 4a

To a 20-mL Schlenk tube, Ru complex (S,S)-2 (3.3 mg, S/C = 1000), 4a (995 mg, 5 mmol), HCO<sub>2</sub>K (421 mg, 5 mmol), H<sub>2</sub>O (4 mL), EtOAc (2.5 mL), and HCO<sub>2</sub>H (0.57 mL, 15 mmol) were added under a N<sub>2</sub> atmosphere, and the mixture was stirred vigorously for 4 h at 60 °C. After completion of the reaction was confirmed by GC analysis, the reaction mixture was extracted with 5 mL of EtOAc three times. The combined organic layer was concentrated under vacuum, and then, the residue was purified by flash chromatography (hexane:EtOAc = 5:1) to afford the pure product 5a in 93% yield.

#### Acknowledgements

We are grateful to Messrs. Yoshihiro Yaguchi, Akihiro Kawaraya, Hiroaki Izumi, Tsuyoshi Kobayashi, and Satoru Moriya and Mse Chikako Kawata, Yumi Kusano, and Noriko Yamamoto of Takasago International Corporation for NMR measurements, mass spectroscopy, and experimental assistance. We also thank Prof. Takeshi Nakai and Prof. Masahiro Terada for helpful discussions.

#### References

- [1] a) S. Hashiguchi, A. Fujii, J. Takehara, T. Ikariya, R. Noyori, J. Am. Chem. Soc. 1995, 117, 7562–7563; b) A. Fujii, S. Hashiguchi, N. Uematsu, T. Ikariya, R. Noyori, J. Am. Chem. Soc. 1996, 118, 2521–2522; c) K. Haack, S. Hashiguchi, A. Fujii, T. Ikariya, R. Noyori, Angew. Chem. Int. Ed. Engl. 1997, 36, 285–288; d) R. Noyori, S. Hashiguchi, Acc. Chem. Res. 1997, 30, 97–102; e) K. Matsumura, S. Hashiguchi, T. Ikariya, R. Noyori, J. Am. Chem. Soc. 1997, 119, 8738–8739; f) S. Gladiali, E. Alberico, Chem. Soc. Rev. 2006, 35, 226–236; g) T. Ikariya, J. Blacker, Acc. Chem. Res. 2007, 40, 1300–1308; h) D. Wang, Q. Chen, S. Lu, Y. Zhou, Chem. Rev. 2012, 112, 2557–2590; i) Y. Li, S. Yu, W. Shen, J. Gao, Acc. Chem. Res. 2015, 48, 2587–2598; j) D. Wang, D. Astruc, Chem. Rev. 2015, 115, 6621–6686.
- [2] a) M. Miyagi, J. Takehara, S. Collet, K. Okano, Org. Proc. Res. Dev. 2000, 4, 346–348; b) S. Komiya, H. Shimizu, I. Nagasaki in Comprehensive Chirality, Vol. 9 (Eds.: E. M. Carreira, H. Yamamoto), Elsevier, Amsterdam, 2012, pp. 83–103; c) T. Remarchuk, F. St-

Jean, D. Carrera, S. Savage, H. Yajima, B. Wong, S. Babu, A. Deese, J. Stults, M. W. Dong, D. Askin, J. W. Lane, K. L. Spencer, *Org. Process Res. Dev.* **2014**, *18*, 1652–1666; d) M. Komiyama, T. Itoh, T. Takeyasu, *Org. Process Res. Dev.* **2015**, *19*, 315–319.

- [3] a) B. C. Vanderplas, K. M. DeVries, D. E. Fox, J. W. Raggon, M. W. Snyder, F. J. Urban, Org. Proc. Res. Dev. 2004, 8, 583-586; b) W. Yang, J. Xu, Y. Xie, Y. Xu, G. Zhao, G. Lin, Tetrahedron: Asymmetry 2006, 17, 1769-1774; c) P. A. Glossop, C. A. L. Lane, D. A. Price, M. E. Bunnage, R. A. Lewthwaite, Kim James, A. D. Brown, M. Yeadon, C. Perros-Hugue, M. A. Trevethick, N. P. Clarke, R. Webster, R. M. Jones, J. L. Burrows, N. Feeder, S. C. J. Taylor, F. J. Spence, J. Med. Chem. 2010, 53, 6640-6652; d) P. D. Koning, I. R. Gladwell, I. B. Moses, M. S. Panesar, A. J. Pettman, N. M. Thomson, Org. Process Res. Dev. 2011, 15, 1247-1255; e) C. Lu, Z. Luo, L. Huang, X. Li, Tetrahedron: Asymmetry 2011, 22, 722-727; f) S. Wei, R. Messerer, S. B. Tsogoeva, Chem. Eur. J. 2011, 17,14380-14384; g) S. Karlsson, J. H. Sörensen, Org. Process Res. Dev. 2012, 16, 586-594; h) H. Uchimoto, M. Ikeda, S. Tanida, K. Ohhashi, Y. Chihara, T. Shigeta, K. Arimitsu, M. Yamashita, K. Nishide, I. Kawasaki, Chem. Pharm. Bull. 2017, 65, 389-395.
- [4] a) Y. Ma, H. Liu, L. Chen, X. Cui, J. Zhu, J. Deng, Org. Lett. 2003, 5, 2103–2106; b) F. Wang, H. Liu, J. Zhu, J. Deng, Y. Jiang, J. Org. Chem. 2005, 70, 9424-9429; c) A. Ros, A. Magriz, H. Dietrich, R. Fernández, E. Alvarez, J. M. Lassaletta, Org. Lett. 2006, 8, 127-130; d) L. Li, J. Wu, F. Wang, J. Liao, H. Zhang, C. Lian, J. Zhu, J. Deng, Green Chem. 2007, 9, 23-25; e) J. Liu, D. Zhou, X. Jia, L. Huang, X. Li, A. S. C. Chan, Tetrahedron: Asymmetry 2008, 19, 1824-1828; f) Z. Zhou, Y. Sun, Catal. Commun. 2009, 10, 1685-1688; g) J. Li, X. Li, Y. Ma, J. Wu, F. Wang, J. Xiang, J. Zhu, Q. Wang, J. Deng, RSC Adv. 2013, 3, 1825–1834; h) D. Zhang, T. Cheng, Q. Zhao, J. Xu, G. Liu, Org. Lett. 2014, 16, 5764-5767; i) Q. Ye, T. Cheng, Y. Zhao, J. Zhao, R. Jin, G. Liu, ChemCatChem 2015, 7, 1801-1805; j) F. Zhou, X. Hu, M. Gao, T. Cheng, G. Liu, Green Chem. 2016, 18, 5651–5657.
- [5] a) E. J. Corey, C. J. Hetal, Angew. Chem. Int. Ed. 1998, 37, 1986–2012; b) H. S. Wilkinson, G. J. Tanoury, S. A. Wald, C. H. Senanayake, Org. Proc. Res. Dev. 2002, 6, 146–148; c) B. T. Cho, Tetrahedron 2006, 62, 7621-7643; d) J. Magano, J. R. Dunetz, Org. Process Res. Dev. 2012, 16, 1156–1184.
- [6] a) A. Goswami, R.L. Bezbaruah, J. Goswami, N. Borthakur, D. Dey, A.K. Hazarika, *Tetrahedron: Asymmetry* 2000, *11*, 3701–3709; b) B. A. Barros-Filho, M. C. F. Oliveira, T. L. G. Lemos, M. C. Mattos, G. Gonzalo, V. Gotor–Fernández, V. Gotor, *Tetrahedron: Asymmetry* 2009, *20*, 1057-1061; c) Y. Ni, C. Li, J. Zhang, N. Shen, U. T. Bornscheuer, J. Xu, *Adv. Synth. Catal.* 2011, *353*, 1213–1217; d) G. Xu, H. Yu, X. Zhang, J. Xu, *ACS Catal.* 2012, *2*, 2566–2571; e) W. Borzęcka, I. Lavandera, V. Gotor, *J. Org. Chem.* 2013, *78*, 7312–7317; f) M. L. Contente, I. Serra, F. Molinari,

R. Gandolfi, A. Pinto, D. Romano, *Tetrahedron* **2016**, 72, 3974–3979.

- [7] a) T. Touge, T. Hakamata, H. Nara, T. Kobayashi, N. Sayo, T. Saito, Y. Kayaki, T. Ikariya, *J. Am. Chem. Soc.* **2011**, *133*, 14960–14963; b) T. Touge, H. Nara, M. Fujiwhara, Y. Kayaki, T. Ikariya, *J. Am. Chem. Soc.* **2016**, *138*, 10084–10087.
- [8] For alkyl tethered ATH catalysts see: a) H. G. Nedden, A. Zanotti-Gerosa, M. Wills, *Chem. Rec.* 2016, 16, 2623-2643; b) A. Kišić, M. Stephan, B. Mohar, *Org. Lett.* 2013, 15, 1614–1617; c) A. Kišić, M. Stephan, B. Mohar, *Adv. Synth. Catal.* 2014, 356, 3193–3198; d) A. Kišić, M. Stephan, B. Mohar, *Adv. Synth. Catal.* 2015, 357, 2540–2546; e) S. Rast, B. Modec, M. Stephan, B. Mohar, *Org. Biomol. Chem.* 2016, 14, 2112–2120; f) A. E. Cotman, D. Cahard, B. Mohar, *Angew. Chem. Int. Ed.* 2016, 55, 5294–5298; g) V. K. Vyas, B. M. Bhanage, *Org. Lett.* 2016, 18, 6436–6439; h) M. Jeran, A. E. Cotman, M. Stephan, B. Mohar, *Org. Lett.* 2017, 19, 2042–2045.
- [9] a) D. J. Cross, J. A. Kenny, I. Houson, L. Campbell, T. Walsgrove, M. Wills, *Tetrahedron: Asymmetry* 2001, 12, 1801–1806; b) P. Peach, D. J. Cross, J. A. Kenny, I. Mann, I. Houson, L. Campbel, T. Walsgrove, M. Wills, *Tetrahedron* 2006, 62, 1864–1876.
- [10] a) T. Hamada, T. Torii, K. Izawa, R. Noyori, T. Ikariya, Org. Lett. 2002, 4, 4373–4376; b) T. Hamada, T. Torii, K. Izawa, T. Ikariya, Tetrahedron 2004, 60, 7411–7417.
- [11] A catalytic sequence of ATH of iodoacetophenones and Sonogashira coupling was recently reported: Y Zhao, R. Jin, Y. Chou, Y. Li, J. Lin, G. Liu, *RSC Adv.* 2017, 7, 22592–22598.
- [12] The ATH of *tert*-butyl bromomethyl ketone with a Ru-prolinamide system: M. Boukachabia, S. Zeror, J. Collin, J.-C. Fiaud, L. A. Zouioueche, *Tetrahedron Lett.* 2011, *52*, 1485–1489.
- [13] a) D.-M. Lee, S.-H. Kwak, K.-I. Lee, Bull. Korean Chem. Soc. 2009, 30, 1317–1324; b) D.-M. Lee, G. Kumaraswamy, K.-I. Lee, Monatsh Chem. 2009, 140, 73–78.
- [14] a) J. Otera, Y. Niibo, H. Nozaki, *Tetrahedron*, 1991, 47, 7625–7634; b) B. T. Cho, S. K. Kang, S. H. Shin, *Bull. Korean Chem. Soc.* 2002, 23, 1693–1694; c) B. T. Cho, S. K. Kang, S. H. Shin, *Tetrahedron: Asymmetry* 2002, 13, 1209–120; d) S. H. Shin, S. K. Kang, B. T. Cho, *Bull. Korean Chem. Soc.* 2003, 24, 1695–1698; e) K. Matsumoto, K. Usuda, H. Okabe, M. Hashimoto, Y. Shimada, *Tetrahedron: Asymmetry* 2013, 24, 108–115.
- [15] a) S. K. Tanielyan, N. Marin, G. Alvez, R. L. Augustine, Org. Process Res. Dev. 2006, 10, 893-898;
  b) F. Yu, J. Zhou, X. Zhang, Y. Sui, F. Wu, L. Xie, A. S. C. Chan, J. Wu, Chem. Eur. J. 2011, 17, 14234-14240; c) K. Huang, H. Wang, V. Stepanenko, M. D. Jesús, C. Torruellas, W. Correa, M. Ortiz-Marciales, J. Org. Chem. 2011, 76, 1883–1886; d) K. Tanaka, K. Otani, T. Murase, S. Nishihote, Z. Urbanczyk-Lipkowska, Bull. Chem. Soc. Jpn, 2012, 85, 709-714;

e) X. Hou, H. Zhang, B. Chen, Z. Guo, A. Singh, A. Goswami, J. L. Gilmore, J. E. Sheppeck, A. J.

Dyckman, P. H. Carter, A. Mathur, Org. Process Res. Dev. 2017, 21, 200–207.

## UPDATE

Selective Asymmetric Transfer Hydrogenation of  $\alpha$ -Substituted Acetophenones with Bifunctional Oxo-Tethered Ruthenium(II) Catalysts

Adv. Synth. Catal. Year, Volume, Page – Page

Yamato Yuki\*, Taichiro Touge, Hideki Nara, Kazuhiko Matsumura, Mitsuhiko Fujiwhara, Yoshihito Kayaki\*, and Takao Ikariya

